Mariner
CTKB icon

Mariner’s Cytek Biosciences CTKB Stock Holding History

Mariner’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,807
Closed -$77.8K – 3591
2026
Q1 		$77.8K Sell
17,807
-758
-4% -$3.58K ﹤0.01% 3364
2025
Q4 		$93.7K Sell
18,565
-8,337
-31% -$38.7K ﹤0.01% 3340
2025
Q3 		$93.3K Buy
26,902
+9,663
+56% +$36.3K ﹤0.01% 3373
2025
Q2 		$58.6K Buy
+17,239
New +$57.4K ﹤0.01% 3325
2025
Q1 		– Sell
-13,098
Closed -$85K – 3473
2024
Q4 		$85K Sell
13,098
-2,219
-14% -$13.2K ﹤0.01% 3215
2024
Q3 		$84.9K Sell
15,317
-215
-1% -$1.22K ﹤0.01% 3118
2024
Q2 		$86.6K Sell
15,532
-2,412
-13% -$14.5K ﹤0.01% 2982
2024
Q1 		$120K Buy
17,944
+1,877
+12% +$14.8K ﹤0.01% 2898
2023
Q4 		$147K Buy
+16,067
New +$101K ﹤0.01% 2775

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mariner's CTKB Position: Q2 2026 in Review

Mariner sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 17,807 shares — an estimated $77.8K sold.

Mariner first reported a position in CTKB in Q4 2023 and held it in 9 quarters. The position peaked at $147K in Q4 2023. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Mariner reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
  • Mariner sold 17,807 Cytek Biosciences shares in Q2 2026, an estimated $77.8K.
  • Mariner first reported a position in Cytek Biosciences in Q4 2023 and held it in 9 quarters.
  • Mariner's Cytek Biosciences position peaked at $147K in Q4 2023.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.